ACHIEVEMENT OF GLYCAEMIC TARGETS WITH CANAGLIFLOZIN IN TRIPLE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS (T2DM)

被引：0
|
作者：
Diels, J. [1 ]
Schubert, A. [2 ]
Hamilton, G. [3 ]
Canovatchel, W. [4 ]
机构：
[1] Janssen Res & Dev, Beerse, Belgium
[2] Janssen Cilag Poland, Warsaw, Poland
[3] Janssen Cilag Ltd, High Wycombe, Bucks, England
[4] Janssen Global Serv LLC, Raritan, NJ USA
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.2048
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDB8
引用
收藏
页码：A598 / A598
页数：1
相关论文
共 50 条
  • [31] Efficacy and Safety of Canagliflozin (CANA) Monotherapy in Subjects With Type 2 Diabetes Mellitus (T2DM) Over 52 Weeks
    Stenloef, Kaj
    Cefalu, William T.
    Kim, Kyoung-Ah
    Jodar, Esteban
    Alba, Maria
    Edwards, Robert
    Tong, Cindy
    Canovatchel, William
    Meininger, Gary
    [J]. DIABETES, 2013, 62 : A303 - A303
  • [32] MobiDiabet: Mobile Telemonitoring System for Patients with Type 2 Diabetes Mellitus (T2DM)
    Alcala Juarez, Anakaren
    Hernandez Villegas, Manuel Alejandro
    Dominguez, Eduardo Lopez
    Hernandez Velazquez, Yesenia
    Dominguez Isidro, Saul
    Ovando Diego, Liliana
    Hernandez Sanchez, Olivia
    De La Calleja, Jorge
    Pomares Hernandez, Saul Eduardo
    Medina Nieto, Maria Auxilio
    [J]. APPLIED SCIENCES-BASEL, 2020, 10 (22): : 1 - 36
  • [33] Development and Validation of Yoga Program for Patients with Type 2 Diabetes Mellitus (T2DM)
    Arun Thulasi
    Vinod Kumar
    Aarti Jagannathan
    Praveen Angadi
    Kundapur Umamaheswar
    Nagarathna Raghuram
    [J]. Journal of Religion and Health, 2022, 61 : 1951 - 1965
  • [34] Effect of Canagliflozin (CANA) in Patients with Type 2 Diabetes Mellitus (T2DM) Based on Age and Estimated Glomerular Filtration Rate (eGFR)
    Gilbert, Richard E.
    Weir, Matthew R.
    Fioretto, Paola
    Law, Gordon
    Usiskin, Keith
    Meininger, Gary
    [J]. DIABETES, 2014, 63 : A267 - A267
  • [35] Development and Validation of Yoga Program for Patients with Type 2 Diabetes Mellitus (T2DM)
    Thulasi, Arun
    Kumar, Vinod
    Jagannathan, Aarti
    Angadi, Praveen
    Umamaheswar, Kundapur
    Raghuram, Nagarathna
    [J]. JOURNAL OF RELIGION & HEALTH, 2022, 61 (03): : 1951 - 1965
  • [36] HDL EFFLUX CAPACITY, AND PARTICLE REMODELLING IN PATIENTS WITH TYPE 1 DIABETES MELLITUS (T1DM) AND TYPE 2 DIABETES MELLITUS (T2DM)
    Byrne, R.
    Curley, S.
    Ahmed, K.
    Ahmed, M.
    Gibney, J.
    Mcgillicuddy, F.
    [J]. ATHEROSCLEROSIS, 2020, 315 : E65 - E66
  • [37] Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Renal Impairment (RI)
    Barnett, Anthony H.
    Mithal, Ambrish
    Manassie, Jenny
    Jones, Russell
    Rattunde, Henning
    Woerle, Hans J.
    Broedl, Uli C.
    [J]. DIABETES, 2013, 62 : A286 - A286
  • [38] THE PREVALENCE OF MICROALBUMINURIA IN CHILDREN WITH TYPE 2 DIABETES MELLITUS (T2DM)
    Yafi, Michael
    [J]. ARCHIVES OF DISEASE IN CHILDHOOD, 2019, 104 : A250 - A250
  • [39] Pregnancy outcomes in women with Type 2 diabetes mellitus (T2DM)
    Tan, Z.
    Pang, W. H.
    Todd, D.
    Halliday, M.
    Gill, F.
    Rhoads, M.
    Sathiskumar, P.
    Gallagher, A.
    de Chazal, R.
    Lawrence, I. G.
    [J]. DIABETIC MEDICINE, 2008, 25
  • [40] THE COST-EFFECTIVENESS OF CANAGLIFLOZIN VERSUS SITAGLIPTIN AS THIRD-LINE THERAPY IN TYPE 2 DIABETES MELLITUS (T2DM) IN A CANADIAN SETTING
    Sabapathy, S.
    Neslusan, C.
    Yoong, K.
    Teschemaker, A. R.
    Johansen, P.
    Willis, M.
    [J]. VALUE IN HEALTH, 2015, 18 (03) : A61 - A61
12345